You must admit, however, that it is a concern. I would like to get an answer from you. How can we be more vigilant? What kind of action is required to monitor both marketing and regulations? There appears to be a vacuum at this time, which means that labelling may pave the way to other types of uses. What kind of action is required? Would it not be appropriate to test these drugs on more people, including children? Children are often administered drugs that were not developed for use in children.
On February 28th, 2008. See this statement in context.